Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.77 |
| ▸ | GSK3B | P49841 | 12/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.77 |
| ▸ | PIM1 | P11309 | 8/20 | 0.74 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.74 |
| ▸ | JAK2 | O60674 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 2/20 | 0.74 |
| ▸ | PRKCG | P05129 | 2/20 | 0.74 |
| ▸ | CDK1 | P06493 | 2/20 | 0.74 |
| ▸ | PRKACA | P17612 | 2/20 | 0.74 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.74 |
| ▸ | CDK2 | P24941 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | GSK3A | P49840 | 2/20 | 0.74 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.74 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.74 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.74 |
| ▸ | PLK4 | O00444 | 1/20 | 0.74 |
| ▸ | CHUK | O15111 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668872 | 0.88 | ROCK2 (0.72) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3666031 | 0.87 | ROCK2 (1.00) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3666012 | 0.86 | ROCK2 (1.00) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3670381 | 0.85 | ROCK2 (1.00) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3673123 | 0.85 | ROCK2 (1.00) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL4289559 | 0.84 | ROCK2 (0.69) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3665942 | 0.83 | ROCK2 (0.70) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3672647 | 0.82 | ROCK2 (0.73) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL4295856 | 0.82 | ROCK2 (0.76) | ROCK2GSK3BAURKBPIM1ROCK1 | |
| SCHEMBL3669811 | 0.81 | ROCK2 (0.81) | ROCK2GSK3BAURKBPIM1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | ROCK2 2842/4885GSK3B 560/4885AURKB 939/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | ROCK2 2842/4885GSK3B 560/4885AURKB 939/4885 |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885AURKB 125/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | ROCK2 2842/4885GSK3B 560/4885AURKB 939/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885GSK3B 1/4885AURKB 125/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | ROCK2 2842/4885GSK3B 560/4885AURKB 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.